In this issue:
SELECT-PsA 1: upadacitinib efficacious in csDMARD non-responders
MAXIMISE: secukinumab elicits durable improvements in symptoms of axial disease
Erectile dysfunction in men with PsA
Adverse body fat distribution in PsA increases risk of heart disease/diabetes
Australian perceptions of PsA management and communication
Ixekizumab elicits rapid and sustained improvements in patient-reported PsA
Carpal tunnel syndrome more frequent in PsA than controls or RA
Real-world drug retention rates with biologic cycling versus swapping strategies
Prevalence of mild cognitive impairment in PsA
Biologic dose spacing leads to higher rates of flares in PsA versus RA or axSpA
Please login below to download this issue (PDF)